Notice of Changes in Officers
Filed with TSE · · 2 pages · English
Towa Pharmaceutical Co., Ltd. (hereinafter, the “Company”) is pleased to announce the following changes in directors as resolved at its Ordinary General Meeting of Shareholders and Board of Directors meeting held on June 24, 2026. 1. New executive structure (As of June 24) (Changes are underlined and bolded.) * Outside Directors as prescribed in Article 2, Item 15 of the Companies Act Itsuro Yoshi
Towa Pharmaceutical Co., Ltd. on 6ix
Earlier from Towa Pharmaceutical
- FY2025 Briefing Script and Q&A Summary of financial results meeting(581K／27P)
- FY2025 Supplementary Material of Financial Results(1.0M／46P)
- FY2025 Consolidated Financial Results for the Year Ended March 31, 2026(Based on Japanese GAAP) (224K／22P)
- FY2025(3rd quarter) Briefing Script and Q&A Summary of financial results meeting(296K／17P)
- FY2025(3rd quarter) Supplementary Material of Financial Results(701K／24P)
Later from Towa Pharmaceutical
- Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. and Transfer of Manufacturing and Marketing Approvals
- Notice of Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation
- Notice of Completion of Payment for the Issuance of 1st Series Class A Preferred Shares through Third-Party Allotment
- Consolidated Financial Results for the Three Months Ended June 30, 2026 (Based on Japanese GAAP)
- FY2026(1st quarter) Briefing Script and Q&A Summary of financial results meeting(319K／15P)
Follow Towa Pharmaceutical into a list and get an email when it puts out news.
Follow Towa Pharmaceutical